Ferroptosis-Mediated Cell Death Induced by NCX4040, The Non-Steroidal Nitric Oxide Donor, in Human Colorectal Cancer Cells: Implications in Therapy.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
14 06 2023
Historique:
received: 18 05 2023
revised: 02 06 2023
accepted: 08 06 2023
medline: 29 6 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: epublish

Résumé

Our recent studies show that the treatment of human ovarian tumor cells with NCX4040 results in significant depletions of cellular glutathione, the formation of reactive oxygen/nitrogen species and cell death. NCX4040 is also cytotoxic to several human colorectal cancer (CRC) cells in vitro and in vivo. Here, we examined the ferroptosis-dependent mechanism(s) of cytotoxicity of NCX4040 in HT-29 and K-RAS mutant HCT 116 colon cell lines. Ferroptosis is characterized by the accumulation of reactive oxygen species (ROS) within the cell, leading to an iron-dependent oxidative stress-mediated cell death. However, its relevance in the mechanism of NCX4040 cytotoxicity in CRCs is not known. We found that NCX4040 generates ROS in CRC cells without any depletion of cellular GSH. Combinations of NCX4040 with erastin (ER) or RSL3 (RAS-selective lethal 3), known inducers of ferroptosis, enhanced CRC death. In contrast, ferrostatin-1, an inhibitor of ferroptosis, significantly inhibited NCX4040-induced cell death. Treatment of CRC cells with NCX4040 resulted in the induction of lipid peroxidation in a dose- and time-dependent manner. NCX4040 treatment induced several genes related to ferroptosis (e.g., CHAC1, GPX4 and NOX4) in both cell lines. Metabolomic studies also indicated significant increases in both lipid and energy metabolism following the drug treatment in HT-29 and HCT 116 cells. These observations strongly suggest that NCX4040 causes the ferroptosis-mediated cell death of CRC cells. Furthermore, combinations of NCX4040 and ER or RSL3 may contribute significantly to the treatment of CRC, including those that are difficult to treat due to the presence of Ras mutations in the clinic. NCX4040-induced ferroptosis may also be a dynamic form of cell death for the treatment of other cancers.

Identifiants

pubmed: 37371096
pii: cells12121626
doi: 10.3390/cells12121626
pmc: PMC10297642
pii:
doi:

Substances chimiques

NCX 4040 0
Nitric Oxide Donors 0
Reactive Oxygen Species 0
Carbolines 0
Glutathione GAN16C9B8O

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Intramural NIH HHS
ID : ZIC ES103363
Pays : United States

Références

Redox Biol. 2020 Jan;28:101328
pubmed: 31574461
Proc Natl Acad Sci U S A. 2020 Dec 22;117(51):32433-32442
pubmed: 33288688
Oxid Med Cell Longev. 2021 Jul 26;2021:9961628
pubmed: 34394837
Front Surg. 2023 Jan 09;9:1060036
pubmed: 36700031
Chem Res Toxicol. 2007 Dec;20(12):1903-12
pubmed: 17975886
Cell Death Dis. 2018 Jul 9;9(7):753
pubmed: 29988039
Cell Mol Life Sci. 2016 Jun;73(11-12):2195-209
pubmed: 27048822
Nitric Oxide. 2011 Aug 1;25(2):95-101
pubmed: 21554971
Cancer Res. 1985 Jul;45(7):3296-304
pubmed: 2988766
Front Oncol. 2017 Jul 31;7:154
pubmed: 28824871
Mol Cell Oncol. 2015 May 26;2(4):e1054549
pubmed: 27308510
Biochem Pharmacol. 1981 Oct;30(20):2797-804
pubmed: 7317075
Trends Mol Med. 2004 Jul;10(7):324-30
pubmed: 15242680
Cell Rep. 2023 Mar 28;42(3):112230
pubmed: 36897777
Front Pharmacol. 2018 Nov 22;9:1371
pubmed: 30524291
React Oxyg Species (Apex). 2016;2(5):361-370
pubmed: 29721549
Oncotarget. 2017 Dec 9;8(70):114588-114602
pubmed: 29383104
Free Radic Biol Med. 2019 Mar;133:162-168
pubmed: 29800655
J Cell Mol Med. 2022 Feb;26(4):1183-1193
pubmed: 35023280
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
J Biol Chem. 2015 Jun 19;290(25):15878-15891
pubmed: 25931127
Biomed Pharmacother. 2022 Sep;153:113524
pubmed: 36076606
Chem Biol. 2008 Mar;15(3):234-45
pubmed: 18355723
PLoS One. 2015 Nov 05;10(11):e0141897
pubmed: 26540186
Nat Cell Biol. 2014 Dec;16(12):1180-91
pubmed: 25402683
J Neurooncol. 2011 Sep;104(2):449-58
pubmed: 21327864
Trends Cell Biol. 2016 Mar;26(3):165-176
pubmed: 26653790
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
Oxid Med Cell Longev. 2021 Dec 26;2021:2915019
pubmed: 34987700
FEBS Lett. 2011 Jan 21;585(2):328-34
pubmed: 21156174
Biochem Biophys Res Commun. 2017 Jan 15;482(3):419-425
pubmed: 28212725
Cell Death Dis. 2022 Jun 10;13(6):544
pubmed: 35688814
Front Cell Dev Biol. 2021 Feb 18;9:639851
pubmed: 33681224
Biochem Biophys Res Commun. 2019 Nov 12;519(3):533-539
pubmed: 31537387
Int J Mol Sci. 2022 Aug 03;23(15):
pubmed: 35955744
Elife. 2014 May 20;3:e02523
pubmed: 24844246
Neural Regen Res. 2020 Mar;15(3):528-536
pubmed: 31571665
Cell Mol Biol Lett. 2020 Feb 27;25:10
pubmed: 32161620
Mol Med. 2022 May 20;28(1):58
pubmed: 35596156
Cancers (Basel). 2022 Dec 31;15(1):
pubmed: 36612280
J Transl Med. 2008 Feb 26;6:9
pubmed: 18302761
Proc Natl Acad Sci U S A. 2005 Nov 22;102(47):17207-12
pubmed: 16282376
Cancer Sci. 2017 Nov;108(11):2187-2194
pubmed: 28837253
Cancers (Basel). 2022 Oct 15;14(20):
pubmed: 36291834
Biochim Biophys Acta Mol Cell Res. 2019 Dec;1866(12):118535
pubmed: 31446062
Free Radic Biol Med. 2010 Apr 15;48(8):983-1001
pubmed: 20116425
Nature. 2015 Apr 2;520(7545):57-62
pubmed: 25799988
J Biol Chem. 2021 Jan-Jun;296:100187
pubmed: 33334878
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nitric Oxide. 2008 Sep;19(2):225-36
pubmed: 18472019
Cell Death Dis. 2020 Feb 3;11(2):88
pubmed: 32015325
Nature. 2007 Jun 14;447(7146):864-8
pubmed: 17568748
Onco Targets Ther. 2020 Jun 11;13:5429-5441
pubmed: 32606760
Cell Death Dis. 2021 Nov 13;12(11):1079
pubmed: 34775496
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
Antioxid Redox Signal. 2013 Oct 10;19(11):1220-35
pubmed: 23157283
Front Oncol. 2022 Mar 17;12:859621
pubmed: 35372041
Colorectal Dis. 2011 Nov;13(11):1230-5
pubmed: 21689324
Signal Transduct Target Ther. 2020 Jun 30;5(1):108
pubmed: 32606298

Auteurs

Birandra K Sinha (BK)

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Carl D Bortner (CD)

Laboratory of Signal Transduction, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Alan K Jarmusch (AK)

Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Erik J Tokar (EJ)

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Carri Murphy (C)

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Xian Wu (X)

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Heather Winter (H)

Immunity, Inflammation, and Disease Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Ronald E Cannon (RE)

Mechanistic Toxicology Branch, Division of Translational Toxicology, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC 27709, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH